Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.53 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.53 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MTOR | P42345 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.38 |
| ▸ | ALB | P02768 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.38 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.38 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.38 |
| ▸ | POLA1 | P09884 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyl Alcohol SCHEMBL27751480 | 0.99 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| Hydrochloric Acid SCHEMBL3345909 | 0.99 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27999217 | 0.89 | PDE3A (0.52) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL31189348 | 0.85 | PDE3A (0.48) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27829248 | 0.85 | PDE4D (0.41) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL28569717 | 0.85 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL23258348 | 0.84 | PDE3A (0.56) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL587469 | 0.83 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL587470 | 0.83 | PDE3A (0.53) | PDE3APDE4DSLC29A1LMNAMTOR | |
| SCHEMBL27712544 | 0.82 | PDE3A (0.46) | PDE3APDE4DSLC29A1LMNAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2211870-A1 | CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2010-08-04 | — | — | EP | claimed |
| WO-2009058394-A1 | CYTIDINE ANALOGS FOR TREATMENT OF MYELODYSPLASTIC SYNDROMES | CELGENE CORPORATION (US) | 2009-05-07 | — | — | WO | claimed |
| WO-2008129530-A1 | GEMCITABINE PRODUCTION PROCESS | CHEMAGIS LTD. (IL) | 2008-10-30 | — | — | WO | claimed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | claimed |
| US-20050159375-A1 | Novel oligonucleotides and related compounds | CHEMGENES CORPORATION | 2005-07-21 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| EP-1483401-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2004-12-08 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| WO-2003076660-A1 | METHOD FOR SELECTING DRUG SENSITIVITY-DETERMINING FACTORS AND METHOD FOR PREDICTING DRUG SENSITIVITY USING THE SELECTED FACTORS | F.HOFFMANN-LA ROCHE AG (CH) | 2003-09-18 | — | — | WO | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| WO-2025096203-A1 | TARGETING A CHIMERIC RNA FOR TREATING CANCER | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-05-08 | — | — | WO | disclosed |
| EP-4281068-A1 | COMBINATION THERAPY SCHEDULES TO TREAT CANCER | Board of Regents, The University of Texas System (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-116642991-A | Combined determination method, kit and application of antitumor drugs | 江苏豪思生物科技有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-114404581-A | Cancer vaccine | 摩登纳特斯有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-114302878-A | Tyrosine kinase non-receptor 1(TNK1) inhibitors and uses thereof | 大日本住友制药肿瘤公司 | 2022-04-08 | — | — | CN | disclosed |
| US-5434254-A | Process for preparing 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1995-07-18 | — | — | US | disclosed |
| EP-0630905-A1 | Process for selectively isolating bêta-2'-deoxy-2',2'-difluorocytidine or its salts | ELI LILLY AND COMPANY (US) | 1994-12-28 | — | — | EP | disclosed |
| US-5223608-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1993-06-29 | — | — | US | disclosed |
| US-4965374-A | Process for and intermediates of 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1990-10-23 | — | — | US | disclosed |
| EP-0306190-A2 | Improvements in or relating to 2',2'-difluoronucleosides | ELI LILLY AND COMPANY (US) | 1989-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159375-A1 | Novel oligonucleotides and related compounds | DCLRE1B, TYMP, DUT | PDE3A 3010/4885PDE4D 1267/4885SLC29A1 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.